Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Kratom Action Presents Regulatory Puzzle For FDA

Oct 04 2013

• By Cathy Dombrowski

Related Content

FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review

Jan 05 2004

FDA Using “All Available Tools” To Remove DMAA From Market

Apr 15 2013

DMAA Warnings Shed Light On FDA NDI Enforcement

May 07 2012

Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues

May 21 2007

NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA

Apr 09 2007

Kava Labeling Revisions Adopted By Trade Groups; FDA Issues Advisory

Apr 01 2002

Labels Offer FDA Clues To Spiked Supplements, Health Fraud

Oct 01 2013

Additional Topics

United States Indonesia Asia Pacific Malaysia Singapore Thailand Regulation OTC Drugs Consumer

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window